Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Cash from Operations (2021 - 2025)

Verrica Pharmaceuticals has reported Cash from Operations over the past 5 years, most recently at 4627000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 4627000.0 for Q4 2025, up 71.2% from a year ago — trailing twelve months through Dec 2025 was 17627000.0 (up 71.07% YoY), and the annual figure for FY2025 was 17627000.0, up 71.07%.
  • Cash from Operations for Q4 2025 was 4627000.0 at Verrica Pharmaceuticals, down from 9700000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for VRCA hit a ceiling of 9700000.0 in Q3 2025 and a floor of 19947000.0 in Q1 2024.
  • Median Cash from Operations over the past 5 years was 8628000.0 (2021), compared with a mean of 8168150.0.
  • Biggest five-year swings in Cash from Operations: crashed 911.56% in 2023 and later soared 213.34% in 2025.
  • Verrica Pharmaceuticals' Cash from Operations stood at 8698000.0 in 2021, then surged by 43.04% to 4954000.0 in 2022, then crashed by 192.83% to 14507000.0 in 2023, then dropped by 10.73% to 16064000.0 in 2024, then soared by 71.2% to 4627000.0 in 2025.
  • The last three reported values for Cash from Operations were 4627000.0 (Q4 2025), 9700000.0 (Q3 2025), and 10023000.0 (Q2 2025) per Business Quant data.